benztropine (Rx)

Brand and Other Names:Cogentin
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 0.5mg
  • 1mg
  • 2mg

injectable solution

  • 1mg/mL
more...

Parkinsonism

Postencephalitic parkinsonism: 1-2 mg/day (range, 0.5-6 mg/day) PO/IV/IM at bedtime or divided q6-12hr; may consider lower dose or 0.5 mg at bedtime in highly sensitive patients; not to exceed 6 mg/day

Idiopathic parkinsonism: 0.5-1 mg qHS initially; titrate dose in 0.5-mg increments every 5-6 days (range 0.5-6 mg daily; some patients may need 4-6 mg/day); not to exceed 6 mg/day

Drug-Induced Extrapyramidal Disorders

1-2 mg IV/IM/PO q8-12hr; reevaluate after 1-2 weeks

Acute dystonia: 1-2 mg IV, then 1-2 mg PO once or twice daily for 7-28 days to prevent recurrence

Dosage Forms & Strengths

tablet

  • 0.5mg
  • 1mg
  • 2mg

injectable solution

  • 1mg/mL
more...

Drug-Induced Extrapyramidal Disorders

<3 years: Not recommended

>3 years: 0.02-0.05 mg/kg IV/IM/PO once daily or q12hr 

Nonanticholinergic antiparkinson agents should be considered first for treatment of Parkinson disease (Beers criteria)

Not well tolerated in elderly, because of bowel, bladder, and CNS effects; avoid use if possible

Should not be used as prophylaxis against extrapyramidal symptoms in elderly

Parkinsonism

0.5 mg PO once daily or q12hr; titrate dose in 0.5-mg increments every 5-6 days; not to exceed 4 mg/day

Next:

Interactions

Interaction Checker

and benztropine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Blurred vision

            Confusion

            Constipation

            Disorientation

            Dry mouth or throat

            Hyperthermia

            Mydriasis

            Nausea

            Paralytic ileus

            Psychosis

            Tachycardia

            Urinary retention

            Visual hallucinations

            Vomiting

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Age <3 years

            Cautions

            Monitor patients with a history of tachyarrhythmia and benign prostatic hyperplasia

            May cause anhidrosis/hyperthermia, which may become severe; use with catuion in hot weather and during exercise; risk is increased in hot environment; consider lowering the dose to prevent impairing heat equilibrium by perspiration

            May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention)

            At higher doses, may be associated with confusion, visual hallucinations or excitement; intensification of symptoms or toxic psychosis may occur in patients with mental disorders

            May cause CNS depression, which may impair ability to operate heavy machinery and tasks that require mental alertness

            In susceptible patients, large doses may cause weakness and inability to move perticular muscles

            Use caution in patients with GI obstruction, tachycardia, prostatic hyperplasia/urinary stricture, and glaucoma

            Response in the elderly >65 years of age may be altered; initiate at low doses and increase PRN while monitoring adverse effects

            Use with caution in children >3 years of age due to anticholinergic effects

            Not recommended for patients with tardive dyskinesia; does not relieve symptoms and may potentially exacerbate symptoms

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Excretion in milk unknown; use with caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Exerts anticholinergic and antihistaminic effects; may prolong action of dopamine by inhibiting its reuptake and storage

            Absorption

            Bioavailability: 29%

            Onset: PO, 1 hr; parenteral, 15 min

            Duration: 6-48 hr

            Distribution

            Protein bound: 95%

            Elimination

            Trace amounts found unchanged in feces

            Previous
            Next:

            Administration

            IV Incompatibilities

            Syringe: Haloperidol

            IV Compatibilities

            Syringe: Chlorpromazine, fluphenazine, metoclopramide, perphenazine

            Y-site: Tacrolimus, fluconazole

            IV Administration

            IV route rarely necessary; use only when PO and IM routes unavailable

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous